Bionomics (BNOX)
(Delayed Data from NSDQ)
$0.83 USD
+0.07 (8.85%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $0.83 0.00 (-0.57%) 4:48 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNOX 0.83 +0.07(8.85%)
Will BNOX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BNOX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNOX
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%
BNOX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate
Bears are Losing Control Over Bionomics Limited Unsponsored ADR (BNOX), Here's Why It's a 'Buy' Now
Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect?
Other News for BNOX
Bionomics files to sell 3.64B ordinary shares for holders
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
Bionomics Secures Solid Financial Runway with $70M Financing Ahead of Phase 3 SAD Study, Earns ‘Buy’ Rating
Bionomics Secures Growth Through Strategic Sale